Related Experiment Video
Updated: Oct 3, 2026
Laparoscopic Non-Mesh Cerclage Pectopexy with Uterine Preservation for Pelvic Organ Prolapse
Published on: October 25, 2024
[Evaluation on the compliance of livial therapy in peri and postmenopausal women]
1Department of Obstetrics and Gynecology, First Hospital of Beijing Medical University, Beijing 100034, China.
Objective:
To evaluate the compliance of livial therapy in peri and postmenopausal women.
Methods:
One hundred thirty four peri and postmenopausal women advised to take Livial were studied for persistency, efficacy and side effect of treatment.
Results:
The mean age is 55.2 years old and post menopausal period is averaged 6.7 years. Their chief complaints were mainly climacteric symptoms(97.0%). Ninety percent of women took livial after prescription. 41.0% of women ceased the therapy after (0.7 +/- 0.8) years of treatment, while 26.2% of them restored after (0.3 +/- 0.2) years due to recurrence of symptoms. The major reason of cease was fear of cancer. The climacteric symptoms were well relieved while body mass index remained unchanged. The occurrence of vaginal bleeding, breast tenderness, edema and gastrointestinal symptoms was 5.6%, 19.7%, 8.2% and 9.0% respectively. The side effect was dose dependent.
Conclusion:
Postmenopausal women had well compliance to Livial despite of mild side effects and ceasing ratio.
